APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vulvar and Vaginal Atrophy Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vulvar and Vaginal Atrophy Therapy Market Outlook and Growth Opportunities 2026

31 December 2025198 pages

Choose your research edition.

Industry ResearchVulvar and Vaginal Atrophy Therapy Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Vulvar and Vaginal Atrophy Therapy Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Vulvar and Vaginal Atrophy Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vulvar and Vaginal Atrophy Therapy Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vulvar and Vaginal Atrophy Therapy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Vulvar and Vaginal Atrophy Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vulvar and Vaginal Atrophy Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vulvar and Vaginal Atrophy Therapy market include Viveve, VenusConcept, ThermiGen LLC, Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall and Alma Lasers, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vulvar and Vaginal Atrophy Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vulvar and Vaginal Atrophy Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vulvar and Vaginal Atrophy Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vulvar and Vaginal Atrophy Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Vulvar and Vaginal Atrophy Therapy Segment by Company

Viveve

VenusConcept

ThermiGen LLC

Lutronic

Hologic

Fotona

BTL Group of Companies

Almirall

Alma Lasers

Vulvar and Vaginal Atrophy Therapy Segment by Type

Vulvar Atrophy Therapy

Vaginal Atrophy Therapy

Vulvar and Vaginal Atrophy Therapy Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Vulvar and Vaginal Atrophy Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vulvar and Vaginal Atrophy Therapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vulvar and Vaginal Atrophy Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vulvar and Vaginal Atrophy Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Vulvar and Vaginal Atrophy Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vulvar and Vaginal Atrophy Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vulvar and Vaginal Atrophy Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vulvar and Vaginal Atrophy Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vulvar and Vaginal Atrophy Therapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vulvar and Vaginal Atrophy Therapy industry.

Chapter 3: Detailed analysis of Vulvar and Vaginal Atrophy Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vulvar and Vaginal Atrophy Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vulvar and Vaginal Atrophy Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vulvar and Vaginal Atrophy Therapy Industry Trends Table 2. Vulvar and Vaginal Atrophy Therapy Industry Drivers Table 3. Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges Table 4. Vulvar and Vaginal Atrophy Therapy Industry Restraints Table 5. Global Vulvar and Vaginal Atrophy Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vulvar and Vaginal Atrophy Therapy Revenue Share by Company (2021-2026) Table 7. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Company (2021-2026) Table 9. Global Vulvar and Vaginal Atrophy Therapy Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vulvar and Vaginal Atrophy Therapy Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vulvar and Vaginal Atrophy Therapy Key Company Manufacturing Base & Headquarters Table 12. Global Vulvar and Vaginal Atrophy Therapy Company, Product Type & Application Table 13. Global Vulvar and Vaginal Atrophy Therapy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vulvar and Vaginal Atrophy Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vulvar Atrophy Therapy Table 18. Significant Companies of Vaginal Atrophy Therapy Table 19. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Type (2021-2026) Table 23. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Type (2027-2032) Table 24. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type (2021-2026) Table 28. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Specialty Clinics Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Ambulatory Surgical Centers Table 32. Significant Companies of Others Table 33. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Application (2021-2026) Table 37. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Application (2027-2032) Table 38. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application (2021-2026) Table 42. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application (2027-2032) Table 43. Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2026) & (K Units) Table 45. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2021-2026) Table 46. Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2027-2032) & (K Units) Table 47. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2027-2032) Table 48. Global Vulvar and Vaginal Atrophy Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Region (2021-2026) Table 51. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Region (2027-2032) Table 53. Global Vulvar and Vaginal Atrophy Therapy Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Vulvar and Vaginal Atrophy Therapy Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Vulvar and Vaginal Atrophy Therapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 58. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2021-2026) Table 59. Global Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 60. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2027-2032) Table 61. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Vulvar and Vaginal Atrophy Therapy Sales Value Market Share by Country (2021-2026) Table 63. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Vulvar and Vaginal Atrophy Therapy Sales Value Market Share by Country (2027-2032) Table 65. Viveve Company Information Table 66. Viveve Business Overview Table 67. Viveve Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 69. Viveve Recent Development Table 70. VenusConcept Company Information Table 71. VenusConcept Business Overview Table 72. VenusConcept Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 74. VenusConcept Recent Development Table 75. ThermiGen LLC Company Information Table 76. ThermiGen LLC Business Overview Table 77. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 79. ThermiGen LLC Recent Development Table 80. Lutronic Company Information Table 81. Lutronic Business Overview Table 82. Lutronic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 84. Lutronic Recent Development Table 85. Hologic Company Information Table 86. Hologic Business Overview Table 87. Hologic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 89. Hologic Recent Development Table 90. Fotona Company Information Table 91. Fotona Business Overview Table 92. Fotona Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 94. Fotona Recent Development Table 95. BTL Group of Companies Company Information Table 96. BTL Group of Companies Business Overview Table 97. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 99. BTL Group of Companies Recent Development Table 100. Almirall Company Information Table 101. Almirall Business Overview Table 102. Almirall Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 104. Almirall Recent Development Table 105. Alma Lasers Company Information Table 106. Alma Lasers Business Overview Table 107. Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 109. Alma Lasers Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Vulvar and Vaginal Atrophy Therapy Distributors List Table 113. Vulvar and Vaginal Atrophy Therapy Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Vulvar and Vaginal Atrophy Therapy Product Image Figure 2. Global Vulvar and Vaginal Atrophy Therapy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vulvar and Vaginal Atrophy Therapy Sales (2021-2032) & (K Units) Figure 5. Global Vulvar and Vaginal Atrophy Therapy Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vulvar and Vaginal Atrophy Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vulvar Atrophy Therapy Image Figure 10. Vaginal Atrophy Therapy Image Figure 11. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Type (2021-2032) Figure 14. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type (2021-2032) Figure 17. Specialty Clinics Image Figure 18. Hospitals Image Figure 19. Ambulatory Surgical Centers Image Figure 20. Others Image Figure 21. Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Application (2021-2032) Figure 24. Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application (2021-2032) Figure 27. Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Vulvar and Vaginal Atrophy Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 32. North America Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 38. South America Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Vulvar and Vaginal Atrophy Therapy Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Vulvar and Vaginal Atrophy Therapy Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Vulvar Atrophy Therapy
  • Vaginal Atrophy Therapy
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Viveve
  • VenusConcept
  • ThermiGen LLC
  • Lutronic
  • Hologic
  • Fotona
  • BTL Group of Companies
  • Almirall
  • Alma Lasers

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  4. 1.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales Volume (2021-2032)
  5. 1.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vulvar and Vaginal Atrophy Therapy Market Dynamics
  1. 2.1 Vulvar and Vaginal Atrophy Therapy Industry Trends
  2. 2.2 Vulvar and Vaginal Atrophy Therapy Industry Drivers
  3. 2.3 Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges
  4. 2.4 Vulvar and Vaginal Atrophy Therapy Industry Restraints
3 Vulvar and Vaginal Atrophy Therapy Market by Company
  1. 3.1 Global Vulvar and Vaginal Atrophy Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Company (2021-2026)
  4. 3.4 Global Vulvar and Vaginal Atrophy Therapy Average Price by Company (2021-2026)
  5. 3.5 Global Vulvar and Vaginal Atrophy Therapy Company Ranking (2024-2026)
  6. 3.6 Global Vulvar and Vaginal Atrophy Therapy Company Manufacturing Base and Headquarters
  7. 3.7 Global Vulvar and Vaginal Atrophy Therapy Company Product Type and Application
  8. 3.8 Global Vulvar and Vaginal Atrophy Therapy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vulvar and Vaginal Atrophy Therapy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vulvar and Vaginal Atrophy Therapy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vulvar and Vaginal Atrophy Therapy Market by Type
  1. 4.1 Vulvar and Vaginal Atrophy Therapy Type Introduction
  2. 4.1.1 Vulvar Atrophy Therapy
  3. 4.1.2 Vaginal Atrophy Therapy
  4. 4.2 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type
  5. 4.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type
  9. 4.3.1 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Type (2021-2032)
  11. 4.3.3 Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type (2021-2032)
5 Vulvar and Vaginal Atrophy Therapy Market by Application
  1. 5.1 Vulvar and Vaginal Atrophy Therapy Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Others
  6. 5.2 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application
  7. 5.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application
  11. 5.3.1 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Application (2021-2032)
  13. 5.3.3 Global Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application (2021-2032)
6 Vulvar and Vaginal Atrophy Therapy Regional Sales and Value Analysis
  1. 6.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2032)
  3. 6.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021-2026
  4. 6.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2027-2032)
  5. 6.3 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Region (2027-2032)
  9. 6.5 Global Vulvar and Vaginal Atrophy Therapy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  12. 6.6.2 North America Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  15. 6.7.2 Europe Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  21. 6.9.2 South America Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vulvar and Vaginal Atrophy Therapy Sales Value Share by Country, 2025 VS 2032
7 Vulvar and Vaginal Atrophy Therapy Country-level Sales and Value Analysis
  1. 7.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
  4. 7.3.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026)
  5. 7.3.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032)
  6. 7.4 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vulvar and Vaginal Atrophy Therapy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vulvar and Vaginal Atrophy Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Viveve
  2. 8.1.1 Viveve Company Information
  3. 8.1.2 Viveve Business Overview
  4. 8.1.3 Viveve Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio
  6. 8.1.5 Viveve Recent Developments
  7. 8.2 VenusConcept
  8. 8.2.1 VenusConcept Company Information
  9. 8.2.2 VenusConcept Business Overview
  10. 8.2.3 VenusConcept Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio
  12. 8.2.5 VenusConcept Recent Developments
  13. 8.3 ThermiGen LLC
  14. 8.3.1 ThermiGen LLC Company Information
  15. 8.3.2 ThermiGen LLC Business Overview
  16. 8.3.3 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio
  18. 8.3.5 ThermiGen LLC Recent Developments
  19. 8.4 Lutronic
  20. 8.4.1 Lutronic Company Information
  21. 8.4.2 Lutronic Business Overview
  22. 8.4.3 Lutronic Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  24. 8.4.5 Lutronic Recent Developments
  25. 8.5 Hologic
  26. 8.5.1 Hologic Company Information
  27. 8.5.2 Hologic Business Overview
  28. 8.5.3 Hologic Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  30. 8.5.5 Hologic Recent Developments
  31. 8.6 Fotona
  32. 8.6.1 Fotona Company Information
  33. 8.6.2 Fotona Business Overview
  34. 8.6.3 Fotona Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio
  36. 8.6.5 Fotona Recent Developments
  37. 8.7 BTL Group of Companies
  38. 8.7.1 BTL Group of Companies Company Information
  39. 8.7.2 BTL Group of Companies Business Overview
  40. 8.7.3 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio
  42. 8.7.5 BTL Group of Companies Recent Developments
  43. 8.8 Almirall
  44. 8.8.1 Almirall Company Information
  45. 8.8.2 Almirall Business Overview
  46. 8.8.3 Almirall Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio
  48. 8.8.5 Almirall Recent Developments
  49. 8.9 Alma Lasers
  50. 8.9.1 Alma Lasers Company Information
  51. 8.9.2 Alma Lasers Business Overview
  52. 8.9.3 Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio
  54. 8.9.5 Alma Lasers Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vulvar and Vaginal Atrophy Therapy Value Chain Analysis
  2. 9.1.1 Vulvar and Vaginal Atrophy Therapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vulvar and Vaginal Atrophy Therapy Sales Mode & Process
  6. 9.2 Vulvar and Vaginal Atrophy Therapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vulvar and Vaginal Atrophy Therapy Distributors
  9. 9.2.3 Vulvar and Vaginal Atrophy Therapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst